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A Genome-wide Association Study
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Adiponectin is associated with obesity and insulin resistance. To date, there has been no genome-wide association study (GWAS) of
adiponectin levels in Asians. Here we present a GWAS of a cohort of Korean volunteers. A total of 4,001 subjects were genotyped by
using a genome-wide marker panel in a two-stage design (979 subjects initially and 3,022 in a second stage). Another 2,304 subjects
were used for follow-up replication studies with selected markers. In the discovery phase, the top SNP associated with mean log
adiponectin was rs3865188 in CDH13 on chromosome 16 (p ¼ 1.69 3 1015 in the initial sample, p ¼ 6.58 3 1039 in the second
genome-wide sample, and p ¼ 2.123 1032 in the replication sample). The meta-analysis p value for rs3865188 in all 6,305 individuals
was 2.82 3 1083. The association of rs3865188 with high-molecular-weight adiponectin (p ¼ 7.36 3 1058) was even stronger in
the third sample. A reporter assay that evaluated the effects of a CDH13 promoter SNP in complete linkage disequilibrium with
rs3865188 revealed that themajor allele increased expression 2.2-fold. This study clearly shows that genetic variants inCDH13 influence
adiponectin levels in Korean adults.Adiponectin in serum decreases insulin resistance and
body weight by increasing lipid oxidation in muscle and
other organs, such as the pancreas and liver.1 Adiponectin
is reduced among obese individuals, as well as those with
diabetes mellitus or coronary heart disease.2,3 Adiponectin
circulates in several forms, principally as a low-molecular-
weight hexamer (~180 kDa) and a high-molecular-weight
multimer (~360 kDa).4 Recent evidence has suggested
that the high-molecular-weight adiponectin may be more
strongly related to several characteristics of the metabolic
syndrome complex.5
A recent family-based study reported a shared herita-
bility of adiponectin and the metabolic syndrome.6 Identi-
fication of genes controlling adiponectin levels may aid
our understanding of how genes influence metabolic syn-
drome and possibly obesity.7,8 Recently, several genome-
wide association studies (GWAS) for adiponectin have
identified ADIPOQ (MIM 605441) and ARL15 as possibly
causal.9–11 Because these genome-wide studies were con-
ducted primarily in samples from European-derived popu-
lations, it remains uncertain whether these findings can be
applied to other populations, especially Asian populations.
Continental Asian populations have a higher percentage of
body fat for a given unit of body mass index (BMI) than do
Europeans.12 However, there has been no published GWAS
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The AmericWe conducted a GWAS of adiponectin levels with the
Human SNP Array 5.0 (Affymetrix) on a discovery sample
of volunteers from the Korean Metabolic Syndrome
Research Initiative study in Seoul. For replication purposes,
we selected samples from two other areas in South Korea:
Ansan and Bundang-gu, both in Gyeonggi Province;
where a genome-wide marker panel was available from
the former. We also tested for association with high-molec-
ular-weight adiponectin by using SNPs identified from the
Seoul discovery sample in a third replication sample.
Subjects for the GWAS were recruited from the Korean
Metabolic Syndrome Research Initiative study in Seoul,
initiated in December 2005. A total of 9,128 individuals
were recruited in 2006, and an additional 17,569 individ-
uals were recruited in 2007.13,14 Therefore, the total Seoul
cohort included 26,697 volunteers. Volunteers from the
first round had routine health examinations at the Health
Promotion Center in University Hospitals between January
2006 and December 2007. From this total, 6,563 individ-
uals were randomly selected for measurement of adiponec-
tin levels. Of the 6,563 individuals with adiponectin, 1,004
individuals were genotyped. A total of 305 individuals
were selected for having very low (33rd percentile) or
very high (66th percentile) adiponectin levels and waist
circumference. Another 699 individuals were randomly
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individuals were selected from our Seoul discovery set (see
Figure S1 available online).
Subjects in a second genome-wide cohort were drawn
from the Ansan cohort, initiated in 2001 as part of the
Korean Genome Epidemiology Study (KoGES). Initial
Ansan samples included 5,020 participants aged 40–69.15
The sampling base for this cohort is Gyeonggi Province,
about 30 km west of Seoul. Members of this cohort have
been examined every 2 years since their baseline visit,
with the third scheduled follow-up study (including family
members) completed in 2008. A total of 5,020 samples
were genotyped. From these 5,020 samples, 3,022 subjects
were randomly selected for measurement of adiponectin
levels.
Subjects for a third cohort were selected from the Korean
Metabolic Syndrome Research Initiative study in the Bun-
dang-gu area. Bundang-gu is also in Gyeonggi Province,
about 30 km south of Seoul. A total of 2,304 individuals
from Bundang-gu were recruited in 2008 and had both
total and high-molecular-weight adiponectin levels
measured.
The Institutional Review Board of Human Research of
Yonsei University approved the study protocol, and
written informed consent was obtained from all subjects.
For all three cohorts, each participant was interviewed
via a structured questionnaire to collect personal history
of cigarette smoking (never smoked, ex-smoker, or current
smoker), alcohol consumption (nondrinker or drinker of
any amount of alcohol), demographic characteristics
(age, gender, etc.), and family history of diabetes. Waist
circumference was measured midway between the lower
rib and iliac crest. For measurement of weight and height,
light clothing was worn. Bodymass index was calculated as
weight (kg) divided by height squared (m2).
For clinical chemistry assays, serum was separated from
peripheral venous blood samples obtained from each
participant after a 12 hr fast and stored at 70C. From
this stored serum, adiponectin levels were measured via
ELISA (Mesdia Co., Ltd.). Intra- and interassay variances
for adiponectin ranged from 6.3% to 7.4% and 4.5% to
8.6%, respectively.16 Quality control (QC) of data was in
accordance with procedures of the Korean Association of
Laboratory Quality Control.
Seoul samples (cohort 1) were genotyped on the Affyme-
trix Genome-Wide Human SNP Array 5.0 at DNALink. For
the data obtained from this chip, internal QC measures
were used: the QC call rate (dynamic model algorithm)
always exceeded 86%, and heterozygosity of X chromo-
some markers identified gender for each individual. Geno-
type calling was performed with the Birdseed (v2) algo-
rithm. A total of 1,004 individuals were genotyped via
this platform in the first discovery phase. However, 10 of
1,004 individuals were removed because of low genotyp-
ing call rates (<95%). PLINK (v1.06) was used to estimate
identity by state (IBS) over all SNPs, and four individuals
were shown to be biological relatives, so one member of
each pair was excluded. Eleven individuals were also546 The American Journal of Human Genetics 87, 545–552, Octoberexcluded as a result of gender mismatches. Therefore,
979 individuals were available for this genome-wide anal-
ysis. A default set of 400,794 SNPs were used for further
analysis, as recommended by Affymetrix. In quality
assurance screening, we flagged SNPs with genotype call
rates < 95%, minor allele frequencies (MAF) < 0.01, and
SNPs showing deviation from Hardy-Weinberg equilib-
rium (HWE) at p < 0.0001. The final set of acceptable
markers included 317,859 autosomal SNPs.
The majority of genomic DNAs from Ansan cohort
participants (cohort 2) were genotyped on this same panel.
Where DNA samples for genotyping were inadequate
(mostly owing to degradation; n ¼ 129), DNA extracted
from Epstein-Barr virus-immortalized lymphoblastoid cell
lines was substituted. DNA samples with low concentra-
tion (n¼ 55) were amplified prior to genotyping according
to the manufacturer’s protocol (QIAGEN). A total of 5,020
samples were genotyped with the Affymetrix Genome-
Wide Human SNP Array 5.0 using 500 ng of genomic
DNA. Markers with low call rate (<95%), low MAF
(<0.01), and/or significant deviation from HWE (p <
0.0001) were excluded, leaving a total of 354,357 markers
from the Ansan cohort.
Genotyping of a total of 2,304 subjects (cohort 3) as a
replication study was conducted for the two strongest
signals selected from the Seoul discovery sample; in
addition, six other SNPs were tagged from the HapMap
Japanese sample panel in International HapMap data as
r2 > 0.3. These eight SNPs were genotyped by using the
TaqMan reaction.17 Duplicate genotyping for about 1%–
2.5% of all samples was performed as a QC check. Only
those SNPs showing a concordance rate in duplicates of
over 99% and a genotype success rate of over 98% were
included in subsequent association analyses.
The distribution of observed p values for the given
SNPs were plotted against the theoretical distribution of
expected p values to construct quantile-quantile (Q-Q)
plots for log10(total adiponectin).
18 Concentration bands
(the shaded region in all Q-Q plots) represent the 95%
confidence interval and were drawn by calculating the
2.5th and 97.5th percentiles of p values under the null
hypothesis, assuming random sampling (Figure S2).
Genotype calls for the Affymetrix Genome-Wide Human
SNP Array 5.0 were determined in batches of approxi-
mately 200–300 samples under the BRLMM algorithm. In
creating a cluster plot for any given SNP, total signal infor-
mation was processed to generate an integrated summary
file. The summary file was then translated into a cluster
plot format by using an algorithm similar to SST1.0 (SNP
signal tool, Affymetrix) (Figure S3).
For expression experiments, we generated four different
constructs for analysis of CDH13 promoter activity. We
generated the constructs composed of 0.6 or 2.7 kb
promoter sequences containing 629 to þ3 and 2782
to þ3 of CDH13, respectively. These DNA fragments were
amplified by PCR from genomic DNAs of the female
donors whose genotypes were different from each other,8, 2010
Table 1. General Characteristics of Study Population
Cohort 1 Cohort 2 Cohort 3
Location Seoul Ansan Bundang-gu
n 979 3,022 2,304
Males, % 56.5 52.4 55.1
Age, years 41.5 5 8.5 54.6 5 7.4 42.9 5 7.8
Waist circumference, cm 81.1 5 9.7 80.1 5 8.6 80.1 5 9.5
Height, cm 166.0 5 8.5 161.8 5 8.2 166.0 5 8.3
Weight, kg 65.6 5 12.1 64.6 5 10.0 64.8 5 11.7
Body mass index, kg/m2 23.7 5 3.1 24.6 5 2.9 23.4 5 3.0
Total adiponectin, mg/ml 6.7 5 6.4a 5.4 5 5.0a 4.4 5 3.3a
Log total adiponectin,
mg/ml
0.82 5 0.29 0.71 5 0.31 0.64 5 0.24
HMW adiponectin, mg/ml   2.7 5 2.0
Log HMW adiponectin,
mg/ml
  0.32 5 0.31
Fasting blood sugar, mg/dl 93.8 5 16.4 99.7 5 31.1 93.7 5 16.7
Systolic blood pressure,
mm Hg
120.8 5 13.9 111.7 5 14.1 117.8 5 14.1
Diastolic blood pressure,
mm Hg
73.8 5 10.4 74.9 5 9.8 76.7 5 11.8
HDL cholesterol, mg/dl 54.1 5 12.8 44.9 5 10.7 52.2 5 12.7
LDL cholesterol, mg/dl 108.7 5 29.2 127.7 5 31.6 117.9 5 30.7
Triglyceride, mg/dl 118.0 5 93.6 141.3 5 89.7 124.9 5 81.9
Smoking status, %
Ex 16.8 24.1 21.9
Current 28.1 16.6 23.2
The following abbreviations are used: HMW, high molecular weight; HDL,
high-density lipoprotein; LDL, low-density lipoprotein. Data shown with 5
are given as mean 5 standard deviation unless indicated otherwise.
a Data given as median 5 interquartile range.one being TT and the other GG, for rs12444338 SNP. The
forward primers were 50-GCAAGCTCGAATTGATCTGTC
AT-30 and 50-AAGGTTTACTGGAGCCACTCT-30 for the 0.6
and 2.7 kb constructs, respectively. The same reverse
primer, 50-CATTTTGACCGACTAGAAGC-30, was used for
both constructs. The PCR product was cloned into
pGEM-T Easy (Promega), and an EcoRI restriction fragment
of this construct was inserted into the EcoRI-digested
pGLuc basic vector (NEB). This yielded the construct
with Gaussian luciferase reporter gene under control of
the 0.6 or 2.7 kb CDH13 promoter sequences. The authen-
ticity of the constructs was determined by DNA se-
quencing of the plasmids. There was no variation in
DNA sequences between T and G variant promoters except
rs12444338SNP itself.
HEK293 cells were grown in Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum, 100 U/ml peni-
cillin, and 100 mg/ml streptomycin at 37C in a humidified
5% CO2 incubator. Cells were plated 1 day ahead of trans-
fection at a density of 4.03 105 cells/ml in six-well culture
plates. For each plasmid or empty pGLuc vector (control
without promoter), 500 ng was transiently cotransfected
with 100 ng of b-galactosidase expression vector using
polyethylenimine. Twenty-four hours posttransfection,
luciferase activity was determined by using a BioLux Gaus-
sia Luciferase Assay kit (NEB) following the manufacturer’s
manual and measured with a luminometer (Turner
Designs). Luciferase activity was normalized against
b-galactosidase activity for transfection efficiency. Three
independent experiments were performed in duplicate.
The values were normalized against background activity
of empty vector control, and the fold difference was calcu-
lated against the T type promoter. Data were compared by
two-tailed Student’s t test.
All biomarkers except adiponectin appeared to be nor-
mally distributed. Therefore, only adiponectin levels were
log transformed (log10). Each SNP was tested for possible
effects on log10(total adiponectin) under an additivemodel
in PLINK. Multivariate linear regressionmodels used in the
study incorporated covariates (age, sex, smoking status,
and BMI). The Seoul discovery data set and two other
data sets were combined via an inverse-variance meta-
analysis method assuming fixed effects with Cochran’s Q
test used to assess between-study heterogeneity.19 All
meta-analysis calculations were performed with the R
program (v2.7.1). We also analyzed the combined Seoul
and Ansan cohorts (n ¼ 4,001).
The majority of individuals were middle-aged (Table 1).
This sample of Korean volunteers had a low BMI on
average, with only 24.1% and 0.8% of men and 26.9%
and 2.5% of women having BMI values R 25 kg/m2
and R 30 kg/m2 (conventional cutoff points defining
overweight and obese), respectively.
Table 2 lists SNPs yielding the top 20 –log10(p values)
from a linear regression model for log10(total adiponectin)
in the 979 discovery set samples when the regression
model included age, sex, smoking status, and BMI as cova-The Americriates. Table S1 lists the next top 30 SNPs. The top SNP
found to be associated with log10(total adiponectin) was
rs3865188 in CDH13 (MIM 601364) on chromosome 16
(p ¼ 1.69 3 1015 in the Seoul sample; p ¼ 6.58 3 1039
in the Ansan sample; p ¼ 2.12 3 1032 in the Bundang-
gu sample) (Figure 1). Five other SNPs in CDH13 were
among the top six SNPs associated with mean log10(total
adiponectin). These six SNPs in CDH13 in the original
discovery sample were replicated in the Ansan cohort,
showing very similar estimated regression coefficients.
The major allele served as the reference allele in these
regression models. In three top SNPs in CDH13, the minor
allele was associated with lower log10(total adiponectin).
However, the minor allele was associated with higher
log10(total adiponectin) for three other SNPs in CDH13.
Two top SNPs (rs3865188 and rs12596316) among these
top 20 were further genotyped using the Bungdang Gu
sample and gave very similar estimated regression
coefficients (specifically b ¼ 0.079 for rs3865188 andan Journal of Human Genetics 87, 545–552, October 8, 2010 547
Table 2. Twenty Most Strongly Associated SNPs from the Seoul Project for Log10(Total Adiponectin) Based on Linear Regression Model
Cohort 1
(n ¼ 979)
Cohort 2
(n ¼ 3,022)
Combined Set
(n ¼ 4,001)
Chromosome SNP Position
Nearest
Gene MAF
Effect
(mg/ml) p Value MAF
Effect
(mg/ml) p Value
Effect
(mg/ml) p Value
16 rs3865188 81208218 CDH13 0.309 0.095 1.685 3 1015 0.296 0.096 6.582 3 1039 0.096 7.793 3 1051
16 rs12596316 81203653 CDH13 0.311 0.088 4.763 3 1013 0.298 0.096 1.731 3 1037 0.094 8.287 3 1047
16 rs7193788 81213661 CDH13 0.470 0.057 3.643 3 1007 0.449 0.071 6.304 3 1024 0.068 2.484 3 1028
16 rs3865186 81204473 CDH13 0.448 0.057 5.844 3 1007 0.458 0.063 9.984 3 1019 0.062 1.634 3 1023
16 rs3852724 81203595 CDH13 0.448 0.057 6.225 3 1007 0.458 0.063 6.727 3 1019 0.062 1.046 3 1023
16 rs3865185 81203963 CDH13 0.448 0.057 6.225 3 1007 0.458 0.064 4.621 3 1019 0.062 7.568 3 1024
3 rs1438545 106535094 ALCAM 0.105 0.089 6.286 3 1007 0.086 0.014 0.2577 0.029 0.006585
1 rs12072620 188794697 FAM5C 0.177 0.074 0.0000009 0.166 0.008 0.4387 0.011 0.1741
1 rs1501501 188795068 FAM5C 0.177 0.074 0.0000009 0.166 0.007 0.4664 0.012 0.1629
13 rs4943398 36083064 LOC400120 0.217 0.064 0.0000029 0.227 0.020 0.02218 0.032 0.00002418
11 rs4936310 110405970 C11orf53 0.229 0.066 0.0000043 0.182 0.018 0.04669 0.035 0.00001446
8 rs436753 88599977 CNBD1 0.318 0.063 0.0000063 0.268 0.014 0.08527 0.006 0.3774
14 rs7148411 19629122 OR4K17 0.230 0.063 0.0000099 0.245 0.008 0.3319 0.008 0.2529
12 rs17251474 91089449 BTG1 0.198 0.064 0.0000114 0.195 0.008 0.3818 0.010 0.1821
5 rs17156226 103533627 NUDT12 0.204 0.068 0.0000119 0.164 0.003 0.7811 0.026 0.002127
15 rs7171526 60497216 FLJ38723 0.118 0.078 0.0000119 0.114 0.008 0.4576 0.010 0.3096
8 rs10957333 66104003 CYP7B1 0.106 0.080 0.0000163 0.106 0.001 0.9349 0.019 0.05887
1 rs2889921 220406261 KIAA1822L 0.167 0.087 0.0000194 0.183 0.018 0.05355 0.036 0.00002391
4 rs11722604 157084201 CTSO 0.192 0.077 0.0000231 0.071 0.004 0.7631 0.052 0.000006402
10 rs2817677 98811818 SLIT1 0.229 0.058 0.0000234 0.214 0.000 0.9617 0.012 0.1117
Table lists theminor allele frequency (MAF), estimated effect size (b) for the 20most significant SNPs identified from the Seoul cohort (cohort 1; n¼ 979), and their
p values in a multiple linear regression model considering age, sex, smoking status, and body mass index under an additive model. MAF, estimated effect size (b),
and p value for the Ansan cohort (cohort 2) are also shown.b ¼ 0.076 for rs12596316, both of which were highly
significant) (Table 3).
BMI was omitted as a covariate in the regression model,
and these results are presented in Table S2. SNP rs3865188
in CDH13was still among the top SNPs, although strength
of association became a bit weaker (p ¼ 2.3 3 1012). The
other five SNPs in CDH13 were still among the top
20 SNPs associated with log10(total adiponectin). The
p value for rs3865188 combined across all three data sets
was 3.33 3 1076 when BMI was omitted (see Table S3).
We also tested these two SNPs for association with high-
molecular-weight adiponectin as a separate phenotype
using the 2,304 replication samples from a third cohort
(Table 4). Six additional SNPs flanking rs3865188 and
rs12596316 were also included in this replication analysis
(Figure S4). The association between high-molecular-
weight adiponectin and rs3865188 was even stronger
(p¼ 7.363 1058) than seen with log10(total adiponectin).
Another SNP, rs4783244, was also very significantly associ-
ated with high-molecular-weight adiponectin (p ¼ 5.72 3
1061) (Table 4).548 The American Journal of Human Genetics 87, 545–552, OctoberAs a first step in understanding the underlying mecha-
nism for genotype AA of rs3865188 with higher adiponec-
tin level at a molecular level, we hypothesized that this
SNP may be in linkage disequilibrium (LD) with another
variant that controls the promoter activity of CDH13,
and DNA sequences containing the A allele may have
higher transcriptional activity than those with the T allele
based on its position in the genomic sequences. We
tested this hypothesis by comparing promoter activities
with both alleles controlling reporter gene expression in
transient transfection experiments. We selected the
rs12444338 SNP, which is in strong LD with rs3865188
and is located 543 bp upstream of the transcription start
site for CDH13. The promoter activity of the G variant
occurring with the A allele at rs3865188 was 1.6 5 0.2,
and this is 2.2-fold higher than that of the T variant for
the 0.6 and 2.7 kb promoters, respectively (Figure S5).
This result suggests that the G variant at rs12444338 has
a strongly increased promoter activity in vitro.
Table S4 lists SNPs yielding the top 20 –log10(p values)
from this linear regression model for mean log10(total8, 2010
Figure 1. Significance of SNPs in CDH13 for All Three Cohorts
Discovery set, n ¼ 979; replication set 1, n ¼ 3,022; replication set 2, n ¼ 2,034. Here, a linear regression model including age, gender,
smoking status, and body mass index was used for each individual SNP. Top panel: plot showing the log10(p value). Black, red, and
white symbols represent data from the discovery study, replication set 1, and replication set 2, respectively. Bottom panel: plot showing
the recombination rate (blue) and cumulative recombination rate measured away from the most highly associated SNP of rs3865188
(yellow). Positions of highly significant SNPs were upstream of CDH13.adiponectin) in the 3,022 Ansan subjects when the regres-
sion model included age, sex, smoking status, and BMI as
covariates (Figure S6). Three SNPs in ADIPOQ were among
the top 20 SNPs associated withmean log10(total adiponec-
tin). Among these three SNPs, two SNPs (rs2241767
and rs266733) were replicated in the 979 Seoul samples.
The most significant SNP in ADIPOQ influencing mean
log10(total adiponectin) was rs2241767 (p ¼ 3.29 3 108
in the 3,022 Ansan sample; p ¼ 0.0012 in the 979 Seoul
sample). We also examined SNPs in ADIPOQ from our
genome-wide marker panel in the combined sample (Seoul
and Ansan cohorts combined had n¼ 4,001). Two of these
three SNPs gave p values at or near genome-wide signifi-
cance in the combined sample (rs2241767, p ¼ 6.72 3
1010; rs864265, p ¼ 1.37 3 107), and four other
SNPs gave nominally significant evidence of an effect on
log10(total adiponectin) (Figure 2). There were a total of
eight SNPs in the genome-wide marker panel, and we
imputed ~16 additional SNPs by using PLINK with theTable 3. Two Most Strongly Associated SNPs from the Seoul Project f
Meta-analysis Results in 6,305 Samples
SNP
Seoul Ansan Bundang-gu
Me
Eff
Effect Size (SE)
(mg/ml)
Effect Size (SE)
(mg/ml)
Effect Size (SE)
(mg/ml)
rs3865188 0.095 (0.0118) 0.096 (0.0073) 0.079 (0.0066) 0
rs12596316 0.088 (0.012) 0.096 (0.0074) 0.076 (0.0065) 0
p values were calculated under a linear regression under an additive model incorpo
are given with standard error (SE).
The AmericHapMapChinese/Japanese sample as the reference popula-
tion to provide better coverage of this gene. Figure 2
summarizes results of this analysis of SNPs in ADPIOQ.
In a cohort of 979 subjects from Seoul genotyped with
the Affymetrix Human SNP Array 5.0 marker panel, linear
regression models incorporating age, gender, smoking
status, and BMI as covariates identified six SNPs in
CDH13 as significantly associated with log10(total adipo-
nectin) levels. A second cohort of 3,022 adults genotyped
on this same platform also showed significant effects
from these same six SNPs (achieving genome-wide signifi-
cance with identical direction of effect). A third replication
cohort of 2,304 Koreans also showed similar regression
coefficients for log10(total adiponectin) and even stronger
effects when levels of high-molecular weight adiponectin
were analyzed.
The cadherin 13 preprotein (CDH13; also known as
T-cadherin) gene spans 1.2 Mb and contains 14 exons.
CDH13 has been reported as an adiponectin receptor.20,21or Log10(Total Adiponectin) Based on Linear Regression Model and
ta-analysis
ect Size (mg/ml) Meta-analysis p Value
Meta-analysis
Heterogeneity Q (p)
.09 2.82 3 1083 3.58 (0.167)
.09 3.09 3 1077 4.13 (0.1268)
rating age, sex, smoking status, and body mass index as covariates. Effect sizes
an Journal of Human Genetics 87, 545–552, October 8, 2010 549
Table 4. Association of SNPs in CDH13 with Log10(Total Adiponectin) and Log10(High-Molecular-Weight Adiponectin) Based on Linear
Regression Model in 2,304 Korean Adults in the Bundang-gu Sample
Total Adiponectin High-Molecular-Weight Adiponectin
SNP Position MAF Effect p Value Effect p Value
rs17244777 81159584 0.232 0.025 0.00069 0.05 8.17 3 108
rs7200895 81202107 0.459 0.035 2.05 3 108 0.069 5.31 3 1018
rs12596316 81203653 0.305 0.076 1.08 3 1030 0.13 8.30 3 1055
rs3865188 81208218 0.298 0.079 2.12 3 1032 0.315 7.36 3 1058
rs7204454 81216695 0.352 0.053 1.78 3 1016 0.084 5.05 3 1025
rs4783244 81219769 0.299 0.079 2.74 3 1033 0.138 5.72 3 1061
rs8047711 81225172 0.194 0.067 3.15 3 1017 0.112 3.47 3 1029
rs12922394 81229828 0.212 0.043 1.19 3 108 0.073 2.66 3 1014
p values were calculated under a linear regression under an additive model, incorporating age, sex, smoking status, and body mass index as covariates.The most significant SNP, rs3865188, is located 17.9 kb
upstream of CDH13 itself. T-cadherin was identified as a
receptor for the hexameric and high-molecular-weight
species of adiponectin, but not for the trimeric or globular
species.20 T-cadherin is expressed in endothelial and
smooth muscle cells, where it may interact with adiponec-
tin. Although transcriptional regulation of CDH13 is not
well understood, evidence that a nucleotide variant in
the promoter region is associated with increased promoter
activity of CDH13 suggests that this variant plays an
important role in expression. Furthermore, we showed550 The American Journal of Human Genetics 87, 545–552, Octoberthat the variants in LD with the promoter are positively
associated with adiponectin levels. Thus, our findings
suggest that level of the receptor, CDH13, may regulate
adiponectin level.
Several GWAS in Western countries have reported
that ADIPOQ exerts a major effect on plasma adiponectin
levels.6,9,10 Ling et al. recently reported a genome-wide
study showing that SNPs within ADIPOQ gave the stron-
gest evidence of association with adiponectin levels (p <
107).9 Another recent GWAS also reported that ADIPOQ
showed the strongest association with adiponectin levelsFigure 2. –log10(p Value) for both
Imputed and Genotyped SNPs in ADIPOQ
in 4,001 Korean Adults
Red dots are genotyped SNPs; open blue
squares are imputed SNPs.
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(p ¼ 4.3 3 1024).10 In the present study, five SNPs in
ADIPOQ were associated with serum total adiponectin at
a more modest p value (p ¼ 1.45 3 108) in the Ansan
sample; however, some of the SNPs were not replicated
in the smaller Seoul sample (Table S4).
The present study showed a weaker association for SNPs
in ADIPOQ with adiponectin levels but much stronger
association for SNPs in CDH13 with adiponectin levels
than in previous studies in Western populations. A recent
GWAS reported a SNP in CDH13 gave the fourth strongest
test of association (p < 2 3 105), which was a much
weaker association than our results.9 One possible reason
is the differences in allele frequency of these SNPs in
CDH13. In the case of rs3865188, allele frequency informa-
tion obtained from HapMap samples showed that Euro-
pean populations were more polymorphic than Asian
populations at this marker.
In the present study, the association of SNPs in CDH13
became even stronger when high-molecular-weight adipo-
nectin levels were used, as compared with total adiponectin
levels. Recent studies have demonstrated that the high-
molecular-weightmultimer formof adiponectin is the active
form of this protein.22 This high-molecular-weight form is
most active in suppression of hepatic glucose production.22
Kobayashi et al. reported that only high-molecular-weight
adiponectin selectively suppressed endothelial cell apo-
ptosis, whereas neither the middle- nor the low-molecular-
weight form of adiponectin had such an effect.23
The strength of our study lies in our assessment of a
unique physiologic measure of adiposity (serum adiponec-
tin) in an Asian population.We also measured high-molec-
ular-weight adiponectin levels in one sample. We adjusted
for potential confounders, including age, sex, smoking
status, and BMI. When BMI was included as a covariate,
rs3865188 in CDH13 was still among the top SNPs, with
even stronger evidence. The question of whether or not
findings from these studies can be generalized to all popu-
lations remains uncertain. Western populations have both
different genetic backgrounds and different dietary
patterns. Genetic studies of adiposity in Asian populations
may not necessarily identify the same set of susceptibility
genes as those in European-derived populations. However,
these three Korean cohorts show strong evidence that
CDH13 on chromosome 16 is associated with serum adipo-
nectin levels.Supplemental Data
Supplemental Data include six figures and five tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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